Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

NCT06912529 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Funder of the study terminated contract

Conditions

B-cell Lymphoma Refractory
B-cell Lymphoma Recurrent

Interventions

PROCEDURE: Leukapheresis
DRUG: Bridging Therapy
DRUG: Lymphodepletion
GENETIC: Axicabtagene Ciloleucel

Sponsor

Universität Münster

Collaborators

[object Object]